论文部分内容阅读
目的：观察克拉屈滨联合中剂量阿糖胞苷（Ara-C）及粒细胞集落刺激因子（G-CSF）（CLAG方案）对于复发/难治性急性髓细胞白血病（AML）的疗效、安全性及毒副作用。方法回顾性分析2013年9月—2015年8月在苏州大学附属第一医院使用克拉屈滨联合治疗的26例复发/难治性AML的疗效及安全性。治疗方案；26例难治复发AML患者均使用CLAG方案；克拉屈滨5 mg/m2，静脉滴注，第1～5天；Ara-C 2 g/m2，静脉滴注，q12 h，第1～5天；G-CSF 300μg，皮下注射，第0～5天。结果完全缓解（CR）率34.6%（9/26），部分缓解（PR）率11.5%（3/26），总有效率（OR）46.1%（12/26）。主要毒副作用为骨髓抑制，其中粒细胞缺乏性感染为88.5%（23/26），而胃肠道反应和肝肾功能受损均为轻度。无化疗相关死亡。结论克拉屈滨联合化疗对于复发/难治性AML有一定疗效；安全性良好，毒副作用轻微。“,”ObjectiveTo analyze the response rate, security and toxicity of salvage chemotherapy combined with cladribine for refractory or relapsed acute myeloid leukemia (RR-AML) patients.Methods We performed retrospective analysis of 26 cases of RR-AML, treated with a salvage chemotherapy regimen with cladribine. The regimen were cladribine 5 mg/m2 confused with intravenous injection d0-5, cytarabine 2 g/m2 treated by intravenous injection d0-5, and G-CSF 300μg by hypodermic injection d0-5.ResultsThe total effective response rate was 46.1%, with a complete remission (CR) rate of 34.6%, partial remission rate of 11.5%. Myelosuppression was the major side-effect, gradeⅣ neutropenia infection occurred to 88.5% of patients. Meanwhile mild gastrointestinal reaction and organ dysfunction were observed.Conclusion Combined chemotherapy with cladribine for RR-AML patients has manifested good effi cacy, and in general it is safe. The observed toxicity and adverse effect are tolerant for most patients.